Biovac
Marcellino Roberts is an experienced human capital professional currently serving as an Employee Support Services Business Partner at Biovac since February 2024. Previously held the position of Senior Human Capital Business Partner at Amaro Foods, focusing on the implementation of initiatives across the Human Capital lifecycle. Marcellino's tenure at GSK spanned from January 2017 to December 2021, where roles included Business Change Manager, responsible for driving M-ERP deployments and managing change across multiple sites, and Learning and Development Manager. Marcellino's early career included academic roles at the University of Cape Town and leadership positions within the Organisational Psychology Students Society. Marcellino holds a Bachelor of Social Sciences (Honours) in Industrial and Organizational Psychology, specializing in Change Management, and a Bachelor of Social Science in Organisational Psychology and Psychology from the University of Cape Town.
Biovac
1 followers
Biovac was founded in 2003 to revive and restore South Africa’s vaccine manufacturing capabilities. We are an African based manufacturer contributing towards filling the gap that exists in the lack of African vaccine manufacturing capability. We recognise that we’ll only achieve this if we match scientific innovation through local biotechnology skills with the most advanced manufacturing technology and global partnerships. We work closely with local academic institutions, global pharmaceutical companies, the public sector as well as private sector. Some of our achievements are described below: We manufacture highly advanced vaccines on behalf of leading international biopharmaceutical companies. Biovac is licensed to manufacture a fully liquid hexavalent vaccine from Sanofi that targets and protects against six childhood diseases. In 2021, we envisage to start the manufacture of a multivalent pneumococcal conjugate vaccine from Pfizer. We supply over 15-million doses of vaccines a year in South Africa and neighbouring countries under strict cold chain conditions. We have built inhouse product development capability and technologies and have successfully out-licensed one of our technologies to international manufacturers. We are working to establish new safeguards against pathogens like group B streptococcus bacteria, a rising cause of sepsis and meningitis in newborns. To do this vital work, we rely on sophisticated technology and, above all, the skills and dedication of more than 350 highly trained team members. Along with our partners, we’ve invested over R800 million in infrastructure and skills development at our manufacturing facilities in Cape Town. These investments are resulting in estimated benefits of more than R500-million a year to the national economy.